Back to Search
Start Over
Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands.
- Source :
-
Journal of comparative effectiveness research [J Comp Eff Res] 2017 Oct; Vol. 6 (7), pp. 575-581. Date of Electronic Publication: 2017 Sep 13. - Publication Year :
- 2017
-
Abstract
- Aim: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs).<br />Methods: We performed a bottom-up cost of illness study in The Netherlands.<br />Results: A total of 136 patients were studied. The mean total costs were €17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of €2039-9346, depending on care. These SREs had median costs of €200-1912.<br />Conclusion: Our data provide a basis to investigate the cost-effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction.
- Subjects :
- Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal economics
Antineoplastic Agents, Hormonal therapeutic use
Bone Neoplasms secondary
Bone Neoplasms therapy
Brachytherapy economics
Cost-Benefit Analysis
Humans
Length of Stay economics
Male
Middle Aged
Netherlands
Prostate-Specific Antigen metabolism
Prostatectomy economics
Quality of Life
Retrospective Studies
Bone Neoplasms economics
Cost of Illness
Prostatic Neoplasms economics
Subjects
Details
- Language :
- English
- ISSN :
- 2042-6313
- Volume :
- 6
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Journal of comparative effectiveness research
- Publication Type :
- Academic Journal
- Accession number :
- 29091013
- Full Text :
- https://doi.org/10.2217/cer-2017-0026